ProCE Banner Activity

Phase II I-SABR: Stereotactic Ablative Radiotherapy ± Nivolumab for Untreated Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative NSCLC

Conference Coverage
Slideset

Current analysis of the phase II I-SABR trial showed SABR plus nivolumab significantly improved 4-year EFS compared with SABR alone in patients with untreated early-stage or isolated lung parenchymal recurrent node-negative NSCLC.

Released: September 20, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc